olaparib (Lynparza) PARP Inhibitor especially effective for BRCA ER/PR+ HER2-

This is a promising future treatment option now that it has been approved.


and more on this:




Author: Becky

I'm a Ph.D candidate, associate lecturer, and breast cancer survivor. I'm studying how patients develop health literacy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s